Human Health Holdings Ltd. (1419) AI Stock Analysis

• Market Cap: HK$311.23M
• Dividend Yield: 3.75%
• Average Volume (3M): 631.27K
• Price to Earnings (P/E): 11.8
• Beta (1Y): 0.30
• Revenue Growth: 9.07%
• EPS Growth: 8.95%
• Country: HK
• Employees: 388
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.03
• Shares Outstanding: 379,552,220
• 10 Day Avg. Volume: 387,000
• 30 Day Avg. Volume: 631,266
• PEG Ratio: 1.34
• Price to Book (P/B): 0.41
• Price to Sales (P/S): 0.49
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: HK$1.00 ▲(25.00% Upside)

The overall score reflects significant financial challenges with declining revenue and income, negatively impacting cash flow. While technical analysis indicates some positive momentum, the high RSI suggests caution. Valuation remains moderate with a reasonable P/E ratio and dividend yield, but financial instability could influence future performance.

Positive Factors

Low Leverage

The company's low leverage indicates a solid financial foundation, reducing risk and providing flexibility to navigate financial challenges.

Strong Cash Position

A strong cash position provides a liquidity buffer, enabling the company to meet obligations and invest in growth opportunities.

Partnership Extension

Extending the partnership term allows the company to explore better exit options, potentially enhancing future returns and shareholder value.

Negative Factors

Declining Revenue

A significant decline in revenue indicates potential loss of market share or demand, challenging the company's ability to sustain operations.

Negative Cash Flow

Negative cash flow suggests liquidity challenges, limiting the company's ability to invest in growth or weather economic downturns.

Profit Decline

A sharp decline in net income impacts profitability and could affect the company's ability to reinvest in its business or pay dividends.

Human Health Holdings Ltd. Business Overview & Revenue Model

Company Description

Human Health Holdings Limited, an investment holding company, provides healthcare services in Hong Kong. The company offers general practice services, including general consultation, diagnostics and preventative health, minor procedure, vaccination, physical check-up, health education, occupational health advisory, Chinese medicine, work injury assessment, telemedicine, COVID-19 related, outreach services, and healthcare related services and products. It also provides specialty services in the areas of general surgery, orthopedics and traumatology, ophthalmology, otorhinolaryngology, pediatrics, obstetrics and gynecology, gastroenterology and hepatology, respiratory medicine, cardiology, pediatric surgery, dermatology and venereology, psychiatry, radiology, urology, nephrology, neurosurgery, anaesthesiology, and oncology, as well as physiotherapy, clinical psychology, medical aesthetics, nutritionist, health and wellness, endoscopy, and medical diagnostics. In addition, the company offers dental services comprising general dentistry, dental implant, 3D guided implant surgery, crown and bridge, periodontal treatment, prosthodontics, oral surgery, orthodontics, endodontics, cosmetic dentistry, teeth whitening, veneers and laser dentistry, advanced oral and maxillofacial surgery, CAD/CAM dentistry, panoramic radiography, and cone-beam computed tomography services. Further, it provides doctors and dentists agreements management, and medical imaging services. As of June 30, 2021, the company operated 58 medical centers and 103 service points. The company was founded in 1997 and is headquartered in Kowloon, Hong Kong. Human Health Holdings Limited is a subsidiary of Treasure Group Global Limited.

How the Company Makes Money

Human Health Holdings Ltd. generates revenue through its extensive network of medical centers by providing medical consultations, diagnostic testing, and health assessment services. The company's key revenue streams include fees for medical consultations and diagnostic services offered to both individual patients and corporate clients. Additionally, Human Health Holdings Ltd. partners with various insurance companies to offer services covered under health insurance plans, which contributes significantly to its earnings. The company also leverages its reputation and network to secure corporate health contracts, providing tailored healthcare solutions to businesses, which further enhances its revenue.

Human Health Holdings Ltd. Financial Statement Overview

Summary

The company faces significant financial challenges, with steep declines in revenue (41%) and net income (87%). While the balance sheet shows low leverage and strong liquidity, negative free cash flow and reduced operating cash flow highlight potential liquidity issues.

Income Statement

The income statement shows a concerning trend with declining revenues and profits over the past year. Revenue fell by approximately 41% from the previous year, and net income dropped by 87%. Gross profit margin stands at 45.7% and net profit margin at 4.1%, indicating the company's ability to manage costs relative to its revenue. However, the steep decline in both revenue and net income highlights significant financial challenges.

Balance Sheet

The balance sheet remains relatively strong, with a low debt-to-equity ratio of 0.19 and an equity ratio of 72.6%, indicating a solid financial foundation with low leverage. The company maintains a strong cash position, evidenced by a net debt of -343 million, suggesting a healthy liquidity buffer. Despite these strengths, the decline in stockholders' equity from the previous year is a concern.

Cash Flow

Cash flow analysis reveals significant issues, with free cash flow turning negative (-28 million) from a positive position in the previous year, indicating potential liquidity challenges. The operating cash flow to net income ratio is low, highlighting inefficiencies in converting profits into cash. The sharp decline in operating cash flow further exacerbates concerns about the company's cash generation capabilities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	644.43M	644.43M	590.82M	1.00B	1.12B	654.71M
Gross Profit	296.57M	296.57M	269.85M	593.24M	659.68M	376.69M
EBITDA	52.32M	52.32M	104.06M	323.46M	513.25M	238.36M
Net Income	26.34M	26.34M	24.19M	180.84M	375.31M	144.45M
Balance Sheet
Total Assets	1.07B	1.07B	1.06B	1.26B	1.16B	612.39M
Cash, Cash Equivalents and Short-Term Investments	439.90M	439.90M	489.58M	641.26M	270.33M	145.26M
Total Debt	134.54M	134.54M	146.46M	182.49M	188.47M	67.08M
Total Liabilities	290.22M	290.22M	289.71M	455.27M	416.67M	202.26M
Stockholders Equity	781.75M	781.75M	766.67M	808.22M	741.95M	410.13M
Cash Flow
Free Cash Flow	33.67M	0.00	-28.17M	580.24M	219.30M	71.44M
Operating Cash Flow	36.28M	0.00	11.34M	664.26M	295.81M	85.49M
Investing Cash Flow	268.48M	0.00	-47.63M	-335.34M	-203.22M	-4.77M
Financing Cash Flow	-42.72M	0.00	-122.66M	-178.28M	-67.45M	-59.30M

Human Health Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.80
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1419, the sentiment is Neutral. The current price of 0.8 is below the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.81, and below the 200-day MA of 0.85, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.75 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1419.

Human Health Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0722	78 Outperform	HK$380.45M	11.93	4.28%	7.10%	-2.88%	-22.83%
2293	75 Outperform	HK$197.21M	11.19	7.84%	8.00%	-21.50%	-43.25%
3689	71 Outperform	HK$601.91M	7.29	5.33%	9.14%	0.47%	50.46%
2189	65 Neutral	HK$450.00M	19.40	5.24%	4.49%	20.85%	-66.81%
1419	55 Neutral	HK$311.23M	11.82	3.40%	3.75%	9.07%	8.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8143	42 Neutral	HK$187.13M	-6.22	-132.60%	―	-30.45%	-734.38%

Human Health Holdings Ltd. Corporate Events

Human Health Holdings Secures Shareholder Approval for Key Resolutions at AGM

Human Health Holdings Limited announced that all resolutions proposed during its Annual General Meeting on December 10, 2025, were approved by shareholders. The resolutions included the adoption of financial statements, declaration of a final dividend, appointment of Ernst & Young as auditors, re-election of directors, and approval of a new share option scheme. This successful AGM reflects strong shareholder support and positions the company for continued strategic initiatives and growth.

The most recent analyst rating on (HK:1419) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Human Health Holdings Ltd. stock, see the HK:1419 Stock Forecast page.

Human Health Holdings Ltd. Announces Annual General Meeting and Key Resolutions

Human Health Holdings Ltd. has announced its upcoming annual general meeting scheduled for December 10, 2025, in Hong Kong. Key agenda items include the adoption of financial statements, declaration of a final dividend, appointment of Ernst & Young as auditors, and re-election of directors. The meeting will also consider resolutions to authorize the board to issue additional shares and securities, which could impact the company’s capital structure and shareholder value.

The most recent analyst rating on (HK:1419) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Human Health Holdings Ltd. stock, see the HK:1419 Stock Forecast page.